Biopharmaceutical company Covistat said on Thursday that it is one step closer in developing the low cost treatment nafamostat for COVID-19 via the acquisition of the technology and intellectual property of Mucokinetica.
In the fight against COVID-19, Dr Peter Cole and Dr Rod Hall, founders of Mucokinetica Ltd and world-leading experts in respiratory diseases and cystic fibrosis, are joining the Covistat team. Mucokinetica's technology and intellectual property will accelerate the efforts to develop a low-cost treatment that helps the body's ability to block the coronavirus and its mutating variations from infiltrating our cells.
The companies added that nafamostat blocks TMPRSS2, the enzyme that enables SARS-CoV-2's spike proteins to gain entry into cells. Whether suffering from mild symptoms at home or acute respiratory failure in a hospital, nafamostat's therapy is expected to reduce the viral load in patients and prevent the progression of COVID-19.
Additionally, Covistat is working to repurpose this proven generic drug nafamostat into oral, intranasal and inhaled therapies for COVID-19 patients, including those in remote and developing regions of the world.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US